Introduction
Methods
Setting
Immunohistochemistry
Comparisons with US SEER data
Statistical analyses
Results
Characteristic | Variable completeness (%) | Category | No. (column % among nonmissing data) |
---|---|---|---|
Among all incident breast cancers (N = 1247) | |||
Sex | 100 | Male | 12 (1.0) |
Female | 1232 (99.0) | ||
Invasiveness in women | 100 | Non-invasive | 19 (1.5) |
Invasive | 1216 (98.5) | ||
Among invasive incident breast cancers in women (N = 1216) | |||
Ethnicity | 99.4 | Black | 1,092 (90.3) |
White | 49 (4.1) | ||
Colored | 46 (3.8) | ||
Asian | 22 (1.8) | ||
Age at diagnosis (years) | <40 | 182 (15.0) | |
40–49 | 290 (23.9) | ||
50–59 | 310 (25.5) | ||
60–69 | 221 (18.2) | ||
70–79 | 147 (12.1) | ||
≥80 | 66 (5.4) | ||
Year of diagnosis | 100 | 2006–2007 | 172 (14.1) |
2008–2009 | 431 (35.4) | ||
2010–2012 | 613 (50.4) | ||
HIV status | 69.0 | Negative | 686 (81.8) |
Positive | 153 (18.2) | ||
Stage | 98.1 | I | 61 (5.1) |
IIA | 211 (17.7) | ||
IIB | 280 (23.5) | ||
IIIA | 148 (12.4) | ||
IIIB-IIIC | 385 (32.3) | ||
IV metastases | 107 (9.0) | ||
Tumor grade | 80.0 | 1 = Well-differentiated | 106 (10.9) |
2 = Moderately-differentiated | 455 (46.8) | ||
3 = Poorly-differentiated | 412 (42.3) | ||
ER | 88.2 | Negative | 376 (35.1) |
Positive: of which | 696 (64.9) | ||
Positive stain score +1 | 96 | ||
+2 | 155 | ||
+3 | 445 | ||
PR | 87.8 | Negative | 500 (46.9) |
Positive, of which: | 567 (53.1) | ||
Positive staining score +1 | 111 | ||
+2 | 163 | ||
+3 | 293 | ||
HER2 | 84.9 | Negative, of which: | 762 (74.1) |
Negative stain score 0 | 404 | ||
+1 | 142 | ||
+2 | 216 | ||
Positive (+3) | 267 (26.0) | ||
Subtypes abbreviations: | 84.5 | Luminal A (ERP and/or PRP, HER2N) | 551 (53.7) |
Luminal B (ERP and/or PRP, HER2P) | 150 (14.6) | ||
HER2P enriched (ERN, PRN, HER2P) | 117 (11.04) | ||
Triple negative (ERN, PRN, HER2N) | 209 (20.4) |
Crude known and unknown receptor status
Receptor status, grade, and stage
ER status | PR status | HER2 status | ER, PR, and HER2 status number of women | ER, PR, and HER2 status row distribution (%) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Number positive | Number negative | % ER negative | Number positive | Number negative | % PR negative | Number positive | Number negative | % HER2 positive | Luminal A | Luminal B | HER2P-enriched | TRN | Luminal A | Luminal B | HER2P-enriched | TRN | ||
All women | 688 | 375 | 35.3† | 559 | 499 | 47.2† | 756 | 265 | 26.0† | 545 | 149 | 116 | 209 | 53.5 | 14.6 | 11.4 | 20.5 | |
Age | <40 | 100 | 54 | 35.1 | 84 | 71 | 45.8 | 102 | 48 | 32.0 | 77 | 29 | 19 | 25 | 51.3 | 19.3 | 12.7 | 16.7 |
40–49 | 177 | 85 | 32.4 | 148 | 113 | 43.3 | 173 | 77 | 30.8 | 128 | 47 | 30 | 45 | 51.2 | 18.8 | 12.0 | 18.0 | |
50–59 | 149 | 121 | 44.8 | 107 | 162 | 60.2 | 199 | 59 | 22.9 | 123 | 28 | 31 | 75 | 47.9 | 10.9 | 12.1 | 29.2 | |
60–69 | 134 | 58 | 30.2 | 106 | 83 | 43.9 | 141 | 42 | 23.0 | 109 | 22 | 20 | 31 | 59.9 | 12.1 | 11.0 | 17.0 | |
70–79 | 90 | 41 | 31.3 | 82 | 49 | 37.4 | 96 | 31 | 24.4 | 74 | 19 | 12 | 22 | 58.3 | 15.0 | 9.5 | 17.3 | |
≥80 | 38 | 16 | 29.6 | 32 | 21 | 39.6 | 45 | 8 | 15.1 | 34 | 4 | 4 | 11 | 64.2 | 7.6 | 7.6 | 20.8 | |
Calendar year | 2006–2007 | 86 | 60 | 41.1 | 72 | 72 | 50.0 | 87 | 37 | 29.8 | 66 | 16 | 21 | 21 | 53.2 | 12.9 | 16.9 | 16.9 |
2008–2009 | 241 | 144 | 37.4 | 186 | 198 | 51.6 | 263 | 116 | 30.6 | 183 | 65 | 51 | 80 | 48.3 | 17.2 | 13.5 | 21.1 | |
2010–2012 | 361 | 171 | 32.1 | 301 | 229 | 43.2 | 406 | 112 | 21.6 | 296 | 68 | 44 | 108 | 57.4 | 13.2 | 8.5 | 20.9 | |
Stage | I | 43 | 13 | 23.2 | 41 | 16 | 28.1 | 40 | 14 | 25.9 | 34 | 10 | 4 | 6 | 63.0 | 18.5 | 7.4 | 11.1 |
II | 319 | 130 | 29.0 | 262 | 184 | 41.3 | 345 | 95 | 21.6 | 262 | 60 | 35 | 81 | 59.8 | 13.7 | 8.0 | 18.5 | |
III | 271 | 202 | 42.7 | 218 | 254 | 53.8 | 314 | 133 | 29.8 | 207 | 68 | 65 | 107 | 46.3 | 15.2 | 14.5 | 23.9 | |
IV | 55 | 30 | 35.3 | 38 | 45 | 54.2 | 57 | 23 | 28.8 | 42 | 11 | 12 | 15 | 52.5 | 13.8 | 15.0 | 18.8 | |
Tumor grade | 1 | 89 | 12 | 11.9 | 76 | 25 | 24.8 | 84 | 15 | 15.2 | 76 | 12 | 3 | 8 | 76.7 | 12.1 | 3.0 | 8.1 |
2 | 331 | 109 | 24.8 | 278 | 161 | 36.7 | 332 | 96 | 22.4 | 276 | 60 | 36 | 55 | 64.6 | 14.1 | 8.4 | 12.9 | |
3 | 189 | 207 | 52.3 | 148 | 246 | 62.4 | 264 | 125 | 32.1 | 138 | 61 | 64 | 125 | 35.6 | 15.7 | 16.5 | 32.2 | |
Missing | 79 | 47 | 37.3 | 57 | 67 | 54.0 | 76 | 29 | 27.6 | 55 | 16 | 13 | 21 | 52.4 | 15.2 | 12.4 | 20.0 | |
Ethnicity | Black | 606 | 351 | 36.7 | 492 | 461 | 48.4 | 679 | 240 | 23.1 | 481 | 131 | 109 | 196 | 52.5 | 14.3 | 11.9 | 20.4 |
White | 32 | 8 | 20.0 | 27 | 13 | 32.5 | 29 | 9 | 23.7 | 24 | 7 | 2 | 5 | 63.2 | 18.4 | 5.3 | 13.2 | |
Colored | 30 | 9 | 23.1 | 26 | 13 | 33.3 | 30 | 8 | 21.1 | 26 | 5 | 3 | 4 | 68.4 | 13.2 | 7.9 | 10.5 | |
Asian | 15 | 5 | 36.7 | 12 | 8 | 40.0 | 14 | 5 | 25.3 | 11 | 4 | 1 | 3 | 57.9 | 21.1 | 6.3 | 15.8 |
Risk ratio of ERN breast cancer | Risk ratio of PRN breast cancer | Risk ratio of HER2P breast cancer | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Factor | Category | Crude RR | Adjusted RR | Crude RR | Adjusted RR | Crude | Adjusted RR | |||
RR | 95% CI | RR | 95% CI | RR | 95% CI | |||||
Age (years) | <40 | 1.08 | 1.11 | 0.84, 1.45 | 1.06 | 1.06 | 0.85, 1.32 | 1.04 | 1.02 | 0.76, 1.38 |
40–49 (ref) | 1 | 1 | - | 1 | 1 | - | 1 | 1 | - | |
50–59 | 1.38 | 1.33 | 1.08, 1.65 | 1.39 | 1.37 | 1.16, 1.61 | 0.74 | 0.74 | 0.56, 0.99 | |
60–69 | 0.93 | 0.92 | 0.70, 1.20 | 1.01 | 1.03 | 0.83, 1.26 | 0.75 | 0.75 | 0.54, 1.03 | |
70–79 | 0.96 | 0.95 | 0.70, 1.29 | 0.86 | 0.87 | 0.67, 1.13 | 0.79 | 0.80 | 0.56, 1.15 | |
≥80 | 0.91 | 0.89 | 0.57, 1.38 | 0.92 | 0.86 | 0.60, 1.23 | 0.49 | 0.49 | 0.25, 0.94 | |
per 5 years |
0.99
| 0.99 |
0.95, 1.02
| 0.99 | 0.99 |
0.97, 1.01
| 0.95 | 0.95 |
0.92, 0.99
| |
P
t
= 0.37
|
P
t
= 0.27
|
p
t
= 0.01
| ||||||||
Calendar year | 2006–2007 | 1.10 |
1.05
|
0.84, 1.32
| 0.97 | 0.91 |
0.76, 1.08
| 0.97 | 0.94 | 0.69, 1.28 |
2008–2009 (ref) | 1 |
1
|
-
| 1 | 1 |
-
| 1 | 1 | - | |
2010–2012 | 0.86 |
0.84
|
0.71, 1.00
| 0.84 | 0.82 |
0.72, 0.94
| 0.71 | 0.70 | 0.56, 0.88 | |
P = 0.03
|
P
t
= 0.09
|
p = 0.01
| ||||||||
Stage | I (ref) | 1 | 1 | - | 1 | 1 | - | 1 | 1 | - |
II | 1.25 | 1.23 | 0.75, 2.02 | 1.47 | 1.55 | 1.00, 2.41 | 0.83 | 0.89 | 0.54, 1.44 | |
III | 1.84 | 1.76 | 1.08, 2.85 | 1.92 | 1.99 | 1.29, 3.09 | 1.15 | 1.22 | 0.76, 1.98 | |
IV | 1.52 | 1.48 | 0.85, 2.57 | 1.93 | 1.92 | 1.20, 3.07 | 1.11 | 1.19 | 0.67, 2.11 | |
P
t
= 0.001
|
P
t
= 0.001
|
p
t
= 0.05
| ||||||||
Tumor grade | 1 (ref) | 1 | 1 | - | 1 | 1 | 1 | 1 | - | |
2 | 2.09 | 1.94 | 1.11, 3.37 | 1.48 | 1.42 | 0.99, 2.04 | 1.48 | 1.30 | 0.79, 2.15 | |
3 | 4.40 | 3.95 | 2.30, 6.79 | 2.52 | 2.37 | 1.67, 3.36 | 2.12 | 1.80 | 1.10, 2.95 | |
Missing | 3.14 | 2.83 | 1.58, 5.04 | 2.18 | 1.96 | 1.34, 2.86 | 1.82 | 1.63 | 0.93, 2.86 | |
p = 0.01
| ||||||||||
Ethnicity | Black (ref) | 1 | 1 | - | 1 | 1 | - | 1 | 1 | - |
Nonblacka | 0.61 | 0.61 | 0.42, 0.89 | 0.71 | 0.73 | 0.55, 0.95 | 0.89 | 0.86 | 0.59, 1.25 | |
P = 0.009
|
P = 0.02
|
p = 0.42
| ||||||||
White | 0.55 | 0.55 | 0.29, 1.01 |
0.67
| 0.69 | 0.44, 1.07 | 0.91 | 0.87 | 0.49, 1.55 | |
Colored | 0.63 | 0.63 | 0.35, 1.11 |
0.69
| 0.70 | 0.45, 1.09 | 0.81 | 0.77 | 0.41, 1.43 | |
Asian | 0.68 | 0.72 | 0.34,1.53 |
0.83
| 0.81 | 0.48, 1.38 | 1.01 | 0.99 | 0.47, 2.09 | |
P = 0.08
|
P = 0.13
|
p = 0.86
|
Time trends
Race
Luminal B (n= 148) vs Luminal A (n= 545) | HER2P enriched (n= 116) vs Luminal A (n= 545) | Triple negative (n= 209) vs Luminal A (n= 545) | ||
---|---|---|---|---|
Odds ratio (95% CI) | Odds ratio (95% CI) | Odds ratio (95% CI) | ||
Age (years) | <40 | 1.04 (0.60, 1.79) | 1.11 (0.58, 2.13) | 0.94 (0.53, 1.65) |
40–49 | 1 | 1 | 1 | |
50–59 | 0.61 (0.36, 1.04) | 1.08 (0.61, 1.91) | 1.70 (1.09, 2.67) | |
60–69 | 0.54 (0.31, 0.96) | 0.75 (0.40, 1.41) | 0.78 (0.46, 1.33) | |
70–79 | 0.69 (0.38, 1.28) | 0.69 (0.33, 1.46) | 0.84 (0.47, 1.52) | |
≥80 | 0.30 (0.10, 0.91) | 0.50 (0.16, 1.53) | 0.84 (0.39, 1.81) | |
P
trend
= 0.003
|
P
trend
= 0.21
|
P
trend
= 0.33
| ||
Calendar year | 2006–2007 | 1 | 1 | 1 |
2008–2009 | 1.57 (0.83, 2.91) | 0.93 (0.51, 1.69) | 1.35 (0.76, 2.39) | |
2010–2012 | 1.00 (0.54, 1.85) | 0.49 (0.27, 0.89) | 1.12 (0.64, 1.94) | |
P
trend
= 0.27
|
P
trend
= 0.003
|
P
trend
= 0.96
| ||
Stage | I–II | 1 | 1 | 1 |
III–IV | 1.41 (0.98, 2.04) | 2.34 (1.53, 3.59) | 1.67 (1.20, 2.32) | |
Tumor grade | 1 | 1 | 1 | 1 |
2 | 1.16 (0.59, 2.31) | 2.54 (0.75, 8.59) | 1.62 (0.73, 3.60) | |
3 | 2.35 (1.17, 4.73) | 8.65 (2.59, 28.9) | 7.70 (3.52, 16.8) | |
Missing | 1.72 (0.74, 4.01) | 4.61 (1.23, 17.26) | 2.99 (1.21, 7.37) | |
Ethnicity | Black | 1 | 1 | 1 |
Nonblacka | 0.95 (0.52, 1.71) | 0.40 (0.17, 0.96) | 0.47 (0.24, 0.89) | |
White | 1.02 (0.42, 2.44) | 0.34 (0.08, 1.49) | 0.50 (0.19, 1.35) | |
Colored | 0.70 (0.26, 1.91) | 0.44 (0.13, 1.53) | 0.36 (0.12, 1.07) | |
Asian | 1.37 (0.41, 4.30) | 0.41 (0.05, 3.27) | 0.63 (0.17, 2.32) |